BioSpace News Archive

Business

FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President

Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.

January 10, 2024
·
2 min read
·
Tyler Patchen
Business

Myrobalan Claims $24M for Portfolio of Neurorestorative Drugs

The Massachusetts–based startup will use the Series A funds to advance its pipeline of oral GPR17, CSF1R and TYK2 candidates.

January 10, 2024
·
2 min read
·
Tristan Manalac
BCG Panel: ‘No Single Approach’ to Maximizing Generative AI in Biotech and Healthcare

For experts on Boston Consulting Group’s generative AI panel, effectively using the technology in the biotech industry will be a collaborative process.

January 10, 2024
·
2 min read
·
Tyler Patchen
Deals

Listen: JPM2024 Day 3 Highlights

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.

January 10, 2024
·
1 min read
·
Lori Ellis
Drug Development

Alcon’s Investigational Drops Show Promising Phase III Data in Dry Eye Disease

Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.

January 10, 2024
·
2 min read
·
Tristan Manalac
JPM2024: Big Tech Poised to Disrupt Biopharma with AI-Based Drug Discovery

On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.

January 10, 2024
·
3 min read
·
Greg Slabodkin
13 Therapies Make Clarivate’s 2024 Drugs to Watch List

Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.

January 10, 2024
·
4 min read
·
Patience Asanga
Gilead Sciences Must Face Consumer Claims Over Older, Lower-Quality Drugs, Court Rules

Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.

January 10, 2024
·
2 min read
·
Connor Lynch
New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

The Centre for Chinese Herbal Medicine Drug Development of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare disease, myofibrillar myopathy.

January 10, 2024
·
4 min read
Drug Development

STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

January 10, 2024
·
11 min read